Maia Fertility

A breakthrough solution for human IVF market

​

Globally, infertility is a significant challenge, with over 80 million couples affected, with approximately 2.5 million ART (Assisted Reproductive Technology) cycles performed each year.

Despite the long history of IVF, the success rate per cycle remains low, at around 30%

​

Embryo implantation failure is the primary reason for unsuccessful pregnancies and is the main limiting factor in reproductive technologies. While there have been advancements in fertility drugs and procedures like IUI and ART, the field of embryo implantation has seen limited progress. Maia Fertility's Fertizyme™ is the first drug developed to specifically address this challenge and has shown a 90% improvement in the rate of embryo implantation in preclinical studies.

​

​

​

​

​

​​